Phase II study of methotrexate, mechlorethamine [chlormethine], vincristine, prednisone, and procarbazine (MMOPP) as primary therapy in infants or young children with primitive neuroectodermal tumors or high-grade astrocytoma.

Trial Profile

Phase II study of methotrexate, mechlorethamine [chlormethine], vincristine, prednisone, and procarbazine (MMOPP) as primary therapy in infants or young children with primitive neuroectodermal tumors or high-grade astrocytoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2013

At a glance

  • Drugs Chlormethine (Primary) ; Methotrexate (Primary) ; Prednisone (Primary) ; Procarbazine (Primary) ; Vincristine (Primary) ; Folinic acid
  • Indications Astrocytoma; Brain cancer; Ependymoma; Medulloblastoma; Neuroectodermal tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Jul 2010 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
    • 26 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top